This activity s approved fo AMA PRA Category 1 Credits™.

EXCLUSIVE INVITATION

for Friends of Faculty and Fellows

—5th Oncology & Pathology™

Towards Harmonization of Pathology and Oncology Standards

VIRTUAL, INTERACTIVE CONFERENCE SATURDAY, JUNE 26, 2021

BENEFITS OF ATTENDING

- Interact and collaborate with peers and colleagues in pathology and medical oncology
- Expand your knowledge of molecular characterization of tumors and novel diagnostic techniques, focusing on hematologic malignancies and genitourinary, gastroinestinal, lung, and breast tumors
- Hear about the latest research on emerging targeted therapies
- Learn about advances in biomarkers for tumor prognostication and prediction of response to therapies
- Obtain insights from leading experts on your most challenging cases in pathology

CO-CHAIRS



Balazs Halmos, MD, MS
Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/
Montefiore Medical Center
Bronx, NY



Lynette M. Sholl, MD Associate Professor, Pathology Harvard Medical School Associate Pathologist, Pathology Brigham and Women's Hospital Boston, MA

Acknowledgment of Commercial Support

This conference is supported by educational grants from Daiichi Sankyo, Inc., Illumina, Inc., and Novartis Pharmaceuticals Corporation.

35% OFF REGISTRATION

for Friends of Faculty & Fellows

Register with code ICOP21LP.



To register, visit

—5th —Annual International Congress on— ONCOLOGY & PATHOLOGY™

Towards Harmonization of Pathology and Oncology Standards



Saturday, June 26, 20211 8:00 AM - 5:00 PM ET



		AGENDA	
Time	End Time	Title	Faculty
8:00 AM	8:05 AM	Welcome, Introductions, and Presession Survey	Lynette M. Sholl, MD
ocus on Gastroii	ntestinal Cancers		
8:05 AM	8:27 AM	Biomarker Testing in Gastroesophageal Cancers (inclduing ERBB2)	Yelena Janjigian, MD
8:27 AM	8:49 AM	Diagnosis and Molecular Characterization of Hepatobiliary Tumors	Rondell Graham, MBBS
8:49 AM	9:11 AM	Keynote: Role of ctDNA and MRD in Solid Tumors (focus on CRC)	Jeanne Tie, MD
9:11 AM	9:16 AM	Question & Answer Session	GI Cancers Faculty Panel
ocus on Genitou	ırinary Cancers		
9:16 AM	9:38 AM	PARP Inhbitors and Other Advances in Prostate Cancer	Daniel Petrylak, MD
9:38 AM	10:00 AM	Update on Biomarker Testing for GU Cancers (including FGFR)	Guru Sonpavde, MD
10:00 AM	10:22 AM	Advances in Immunotherapies and Associated Biomarkers in Genitourinary Malignancies	Matthew Galsky, MD, FASCO
10:22 AM	10:27 AM	Question & Answer Session	GU Cancers Faculty Panel
10:27 AM	10:47 AM	Break	
ocus on Hemato	logic Malignancies		
10:47 AM	11:09 AM	Role of Next Generation Sequencing in Testing for Mutations in Hematologic Malignancies	Annette S. Kim, MD, PhD
11:09 AM	11:31 AM	Clonal Hematopoiesis of Indeterminate Potential and Treatment of Myeloid Malignancies.	Benjamin Ebert, MD
11:31 AM	11:53 AM	Keynote: Advances in MRD in Hematologic Malignancies	C. Ola Landgren, MD
11:53 AM	11:58 AM	Post-session Survey	Lynette M. Sholl, MD
11:58 AM	12:03 PM	Question & Answer Session	Hematologic Malignancies Faculty Pa
11:58 AM	12:58 PM	Lunch	
ocus on Breast (
12:58 PM	1:08 PM	Afternoon Session Welcome and Pre-session survey	Balazs Halmos MD
1:08 PM	1:30 PM	Genomics of Breast Cancer Evolution	Christina Curtis, PhD, MSc
1:30 PM	1:52 PM	Novel Prognostic Markers and Associated Therapeutics in Advanced and Metastatic Breast Cancer	Lajos Pusztai, M.D, D.Phil.
1:52 PM	1:57 PM	Question & Answer Session	Breast Cancer Faculty Panel
lew Avenues on	Cancer Biomarker	s	
1:57 PM	2:19 PM	HPV and EBV in Head and Neck Cancer	Barbara Burtness, MD
2:19 PM	2:41 PM	Keynote: Biomarkers for Treatment and Predicting Response to IO Across Tumors	Kurt Schalper, MD
2:41 PM	2:46 PM	Question & Answer Session	Biomarkers Faculty Panel
2:46 PM	3:06 PM	Break	
ocus on Lung Ca	ncers		
3:06 PM	3:28 PM	Molecular Profiling of Lung Carcinoma and Mesotheliomas	Sanja Dacic MD
3:28 PM	3:50 PM	Neo-adjuvant therapy in Lung Cancer	Jarushka Naidoo, MD
3:50 PM	4:12 PM	Keynote: Role of ctDNA in Lung Neoplasms	Ben Levy, MD
4:12 PM	4:34 PM	Novel Targets and Evolving Treatment Strategies in NSCLC (including ERBB2, Exon20, MET, EGFR)	Balazs Halmos, MD Lynette M. Sholl, MD
4:34 PM	4:42 PM	Post-session survey	Balazs Halmos, MD
4:42 PM	4:47 PM	Question & Answer Session	Lung Cancer Faculty Panel
7.74 191	T.T/ IVI	and the second s	Lang Cancer ractity raffer